milnacipran has been researched along with fluoxetine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morphy, R; Rankovic, Z | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ansseau, M; Bartholomé, F; Bataille, M; Charles, G; Darimont, P; De Wilde, J; Devoitille, JM; Papart, P; Schittecatte, M; Troisfontaines, B | 1 |
| Lucki, I; Rénéric, JP | 1 |
| Ansseau, M; Corruble, E; Guelfi, JD; Plétan, Y; Samuelian, JC; Tonelli, I; Tournoux, A | 1 |
| Bouvard, M; Rénéric, JP; Stinus, L | 2 |
| Hashimoto, S; Hattori, T; Kawasaki, K; Kitamura, Y; Miki, N; Mochizuki, D; Otsuka, Y; Tsujita, R; Yamada, S | 1 |
| Hemrick-Luecke, SK; Iyengar, S; Simmons, RM; Webster, AA; Xu, JY | 1 |
| Dziedzicka-Wasylewska, M; Filip, M; Inan, SY; Przegaliński, E; Wydra, K | 1 |
| Chee, IS; Choe, BM; Ham, BJ; Jung, HY; Kee, BS; Kim, JB; Lee, C; Lee, MS; Oh, BH; Oh, KS; Paik, IH; Yeon, BK | 1 |
| Chassard, D; Hermann, P; Puozzo, C | 1 |
| Bévalot, F; Fanton, L; Gaillard, Y; Grait, H; Le Meur, C; Malicier, D | 1 |
| Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T | 1 |
| Alaux-Cantin, S; André, E; Houchi, H; Legastelois, R; Naassila, M; Pierrefiche, O; Simon O'Brien, E; Vilpoux, C | 1 |
| Linderoth, B; Meyerson, BA; Song, Z | 1 |
| Makuch, W; Mika, J; Przewlocka, B; Rojewska, E; Zychowska, M | 1 |
| Abe, M; Mori, Y; Nakata, S; Ochi, S; Ueno, S; Yamazaki, K; Yoshino, Y | 1 |
| Chen, M; Hoshino, H; Obata, H; Saito, S; Yang, Y | 1 |
| Alexander, KS; Miller, LL; Patton, TB; Rodriguez, TR; Sarfo, AN | 1 |
2 review(s) available for milnacipran and fluoxetine
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for milnacipran and fluoxetine
| Article | Year |
|---|---|
Controlled comparison of milnacipran and fluoxetine in major depression.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Lorazepam; Male; Middle Aged; Milnacipran; Patient Dropouts; Psychiatric Status Rating Scales | 1994 |
A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Milnacipran; Personality Inventory; Treatment Outcome | 1998 |
Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Topics: Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Female; Fluoxetine; Humans; Korea; Male; Middle Aged; Milnacipran; Safety; Treatment Outcome | 2005 |
Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran.
Topics: Adult; Area Under Curve; Cyclopropanes; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Half-Life; Humans; Male; Metabolic Clearance Rate; Methods; Milnacipran; Nausea; Selective Serotonin Reuptake Inhibitors; Time Factors; Vomiting | 2006 |
16 other study(ies) available for milnacipran and fluoxetine
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Cyclopropanes; Desipramine; Duloxetine Hydrochloride; Fluoxetine; Male; Milnacipran; Motor Activity; Rats; Rats, Sprague-Dawley; Thiophenes | 1998 |
Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Behavior, Animal; Cyclopropanes; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Idazoxan; Male; Milnacipran; Motor Activity; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2001 |
Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Behavior, Animal; Binding, Competitive; Brain Chemistry; Conditioning, Psychological; Cyclopropanes; Dose-Response Relationship, Drug; Fear; Fluoxetine; Fluvoxamine; Imipramine; Male; Maprotiline; Microdialysis; Milnacipran; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Prefrontal Cortex; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cell Surface; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming; Synaptosomes; Time Factors | 2002 |
In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Clonidine; Cyclopropanes; Depression; Desipramine; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Mianserin; Milnacipran; Mirtazapine; Motor Activity; Norepinephrine; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Selective Serotonin Reuptake Inhibitors; Swimming | 2002 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cyclohexanols; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Duloxetine Hydrochloride; Fluoxetine; Formaldehyde; Gabapentin; gamma-Aminobutyric Acid; Male; Methyltyrosines; Milnacipran; Neuromuscular Junction; Norepinephrine; p-Chloroamphetamine; Pain; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Thiophenes; Venlafaxine Hydrochloride | 2004 |
Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Opioid; Animals; Antidepressive Agents; Biogenic Monoamines; Conditioning, Operant; Cyclohexanols; Cyclopropanes; Discrimination, Psychological; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Fluoxetine; Male; Milnacipran; Morphine; Morpholines; Naloxone; Narcotic Antagonists; Nomifensine; Rats; Rats, Wistar; Reboxetine; Receptors, Opioid, mu; Selective Serotonin Reuptake Inhibitors; Sodium Chloride; Tramadol; Venlafaxine Hydrochloride | 2004 |
Fatal intoxication with milnacipran.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Chromatography, High Pressure Liquid; Cyclopropanes; Female; Fluoxetine; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Milnacipran; Nordazepam; Oxazepam; Phenothiazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide | 2008 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger | 2009 |
Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats.
Topics: Alcoholism; Analysis of Variance; Animals; Antidepressive Agents; Central Nervous System Depressants; Conditioning, Operant; Cyclopropanes; Desipramine; Disease Models, Animal; Dose-Response Relationship, Drug; Ethanol; Extinction, Psychological; Female; Fluoxetine; Locomotion; Male; Mice; Mice, Inbred DBA; Milnacipran; Rats; Rats, Wistar; Self Administration | 2011 |
The interaction between antidepressant drugs and the pain-relieving effect of spinal cord stimulation in a rat model of neuropathy.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Cyclopropanes; Electrodes, Implanted; Fluoxetine; Ligation; Male; Milnacipran; Pain; Pain Management; Pain Measurement; Peripheral Nervous System Diseases; Physical Stimulation; Rats; Rats, Sprague-Dawley; Sciatic Neuropathy; Selective Serotonin Reuptake Inhibitors; Spinal Cord; Transcutaneous Electric Nerve Stimulation | 2011 |
The influence of microglia activation on the efficacy of amitriptyline, doxepin, milnacipran, venlafaxine and fluoxetine in a rat model of neuropathic pain.
Topics: Amitriptyline; Animals; Antidepressive Agents; Calcium-Binding Proteins; Cyclohexanols; Cyclopropanes; Doxepin; Fluoxetine; Ganglia, Spinal; Hyperalgesia; Male; Microfilament Proteins; Microglia; Milnacipran; Neuralgia; Rats, Wistar; Sciatic Nerve; Spinal Cord; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Antidepressant action via the nitric oxide system: A pilot study in an acute depressive model induced by arginin.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Arginine; Cyclopropanes; Depression; Fluoxetine; Male; Mianserin; Milnacipran; Mirtazapine; Nitric Oxide; Nitric Oxide Synthase; Pilot Projects; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2015 |
Spinal dopaminergic involvement in the antihyperalgesic effect of antidepressants in a rat model of neuropathic pain.
Topics: Amitriptyline; Analgesics; Animals; Antidepressive Agents; Cyclopropanes; Disease Models, Animal; Dopamine; Dopamine Antagonists; Duloxetine Hydrochloride; Fluoxetine; Hyperalgesia; Male; Milnacipran; Neuralgia; Pain Threshold; Rats, Sprague-Dawley; Spinal Cord Dorsal Horn; Sulpiride | 2017 |
Effects of monoamine uptake inhibitors on pain-related depression of nesting in mice.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Bupropion; Citalopram; Conditioning, Operant; Dopamine Uptake Inhibitors; Fluoxetine; Ketoprofen; Lactic Acid; Male; Mice; Mice, Inbred ICR; Milnacipran; Nesting Behavior; Pain; Receptors, Opioid, kappa; Self Stimulation | 2019 |